Mona El-Hashimy

1.4k total citations
19 papers, 708 citations indexed

About

Mona El-Hashimy is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Mona El-Hashimy has authored 19 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Mona El-Hashimy's work include Advanced Breast Cancer Therapies (10 papers), PI3K/AKT/mTOR signaling in cancer (9 papers) and Cancer Treatment and Pharmacology (5 papers). Mona El-Hashimy is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), PI3K/AKT/mTOR signaling in cancer (9 papers) and Cancer Treatment and Pharmacology (5 papers). Mona El-Hashimy collaborates with scholars based in United States, Switzerland and Canada. Mona El-Hashimy's co-authors include Blaise C. Martin, Andrzej S. Królewski, James H. Warram, Ronald J. Sigal, J. Stuart Soeldner, Matthias Geberth, Martine Piccart, Mario Campone, Hope S. Rugo and José Baselga and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Mona El-Hashimy

18 papers receiving 677 citations

Peers

Countries citing papers authored by Mona El-Hashimy

Since Specialization

Citations

This map shows the geographic impact of Mona El-Hashimy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mona El-Hashimy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mona El-Hashimy more than expected).

Fields of papers citing papers by Mona El-Hashimy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mona El-Hashimy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mona El-Hashimy. The network helps show where Mona El-Hashimy may publish in the future.

Co-authorship network of co-authors of Mona El-Hashimy

This figure shows the co-authorship network connecting the top 25 collaborators of Mona El-Hashimy. A scholar is included among the top collaborators of Mona El-Hashimy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mona El-Hashimy. Mona El-Hashimy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Pharmacokinetics and Safety of Multiple-Dose Alpelisib in Participants with Moderate or Severe Hepatic Impairment: A Phase 1, Open-Label, Parallel Group Study 2023 ·Journal of Cancer ·Thomas Marbury, Mona El-Hashimy, Lars Blumenstein, (unknown), (unknown), (unknown), (unknown)	1
2	Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study 2020 ·ESMO Open ·Mark Rosenthal, Paul M. Clément, Mario Campone, Miguel Gil‐Gil, John DeGroot, Olivier Chinot, Ahmed Idbaïh, Hui Gan, Jeffrey Raizer, Patrick Y. Wen, Estela Pineda, (unknown), David Mills, Mona El-Hashimy, Warren Mason	27
3	Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma 2020 ·ESMO Open ·Patrick Y. Wen, Jordi Rodón, Warren Mason, J.T. Beck, John DeGroot, (unknown), David Mills, Mona El-Hashimy, Mark Rosenthal	26
4	Abstract A050: PIK3CA mutation status in tumor tissue and ctDNA as a biomarker for PFS in patients with HR+, HER2- ABC treated with buparlisib or placebo plus fulvestrant: results from the BELLE-2 and BELLE-3 randomized studies 2018 ·Molecular Cancer Therapeutics ·José Baselga, Dalila Sellami, Mona El-Hashimy, Bharani Dharan, Ying Wang, Nicolas Scheuer, B. Sankaran, Angelo Di Leo	5
5	Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment 2017 ·Cancer Research ·Angelo Di Leo, Keun Seok Lee, Eva Ciruelos, Per Eystein Lønning, Wolfgang Janni, Ruth O’Regan, (unknown), Dimitar Kalev, Daniel Egle, Tibor Csőszi, Roberto Bordonaro, Thomas Decker, (unknown), Sibel Blau, Alessio Schirone, Denis Weber, Mona El-Hashimy, Bharani Dharan, Dalila Sellami, Thomas Bachelot	38
6	BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment. 2015 ·Journal of Clinical Oncology ·Angelo Di Leo, Eva Ciruelos, Wolfgang Janni, Per Eystein Lønning, Ruth O’Regan, Michael Hubalek, Tibor Csőszi, Thomas Decker, Vivianne C. G. Tjan‐Heijnen, Denis Weber, Mona El-Hashimy, (unknown), Cristian Massacesi, Thomas Bachelot	5
7	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 2014 ·Annals of Oncology ·Hope S. Rugo, Kathleen I. Pritchard, Michael Gnant, Shinzaburo Noguchi, Martine Piccart, G. N. Hortobagyi, José Baselga, Alejandra Perez, Matthias Geberth, Tibor Csőszi, E. Chouinard, Vichien Srimuninnimit, Puttisak Puttawibul, Janice F. Eakle, Wentao Feng, (unknown), Mona El-Hashimy, T Taran, Howard A. Burris	93
8	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2 2013 ·JNCI Journal of the National Cancer Institute ·Michael Gnant, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Howard A. Burris, Martine Piccart, Gabriel N. Hortobágyi, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Matthias Geberth, Lowell L. Hart, Peyman Hadji, Mona El-Hashimy, (unknown), Tetiana Taran, Tarek Sahmoud, David Lebwohl, Mario Campone, Kathleen I. Pritchard	77
9	A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy 2013 ·Breast Cancer Research and Treatment ·Sara A. Hurvitz, Florence Dalenc, Mario Campone, Ruth O’Regan, Vivianne C. G. Tjan‐Heijnen, Joseph Gligorov, Antonio Llombart‐Cussac, Haresh Jhangiani, Hamid Mirshahidi, Elizabeth Tan-Chiu, Sara Miao, Mona El-Hashimy, Jeremie Lincy, Tetiana Taran, Jean‐Charles Soria, Tarek Sahmoud, Fabrice André	58
10	Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 2013 ·Breast Cancer Research and Treatment ·J. Thaddeus Beck, Gabriel N. Hortobágyi, Mario Campone, Fabienne Lebrun, Ines Deleu, Hope S. Rugo, Barbara Pistilli, Norikazu Masuda, Lowell L. Hart, Bohuslav Melichar, Shaker R. Dakhil, Matthias Geberth, (unknown), Daniel Y.C. Heng, Thomas Brechenmacher, Mona El-Hashimy, (unknown), François Ringeisen, Martine Piccart	75
11	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). 2013 ·Journal of Clinical Oncology ·Ruth O’Regan, Mustafa Özgüroğlu, Fabrice André, Masakazu Toi, Guy Jérusalem, Sharon Wilks, Claudine Isaacs, Binghe Xu, Norikazu Masuda, Francis P. Arena, Denise A. Yardley, Yoon Sim Yap, Pabak Mukhopadhyay, (unknown), Mona El-Hashimy, Tanya Taran, Tarek Sahmoud, David Edward Lebwohl, Luca Gianni	41
12	PO59 EFFICACY AND SAFETY OF EVEROLIMUS PLUS EXEMESTANE COMBINATION THERAPY VERSUS MONOTHERAPY WITH EVEROLIMUS OR CAPECITABINE IN HR+, HER2− BREAST CANCER: A MULTI-CENTER, OPEN-LABEL, PHASE 2 TRIAL BOLERO-6 2013 ·The Breast ·Richard de Boer, Guy Jérusalem, Sara A. Hurvitz, Bent Ejlertsen, Mona El-Hashimy, Wentao Feng, Tetiana Taran, Howard A. Burris	2
13	Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer 2012 ·Journal of Clinical Oncology ·Nicoletta Colombo, E. Kutarska, Meletios Α. Dimopoulos, Duk‐Soo Bae, I Rzepka-Górska, Mariusz Bidziński, Giovanni Scambia, Svend Aage Engelholm, Florence Joly, Dirk Weber, Mona El-Hashimy, Jingjin Li, Farida Souami, (unknown), Silke Engelholm, Aristotelis Bamias, Peter E. Schwartz	95
14	Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets). 2012 ·Journal of Clinical Oncology ·Lowell L. Hart, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris, Martine Piccart, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Mona El-Hashimy, (unknown), Ashok Panneerselvam, Tanya Taran, Gabriel N. Hortobágyi, Tarek Sahmoud, David Edward Lebwohl, Michael Gnant	0
15	Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets). 2012 ·Journal of Clinical Oncology ·Michael Gnant, José Baselga, Hope S. Rugo, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris, Martine Piccart, Lowell L. Hart, Janice F. Eakle, Hirofumi Mukai, Hiroji Iwata, Mona El-Hashimy, (unknown), Tanya Taran, Tarek Sahmoud, David Edward Lebwohl, Gabriel N. Hortobágyi	5
16	Clinical importance of including new and nontarget lesion assessment of disease progression (PD) to predict overall survival (OS): Implications for randomized phase II study design. 2012 ·Journal of Clinical Oncology ·William Mietlowski, Weichao Bao, Patricia A. Wood, Denise Williams, Mona El-Hashimy, Céline Sarr, Andrew M. Stein, Michael Shi, Dirk Weber, Dany Habr, (unknown)	4
17	A Phase II Study of Patupilone (EPO906) in Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer 2012 ·Willem M. Smit, Jozef Šufliarský, Theresa L. Werner, Don S. Dizon, Mária Wagnerová, Holger W. Hirte, Nick M. Spirtos, Amit M. Oza, Luc Dirix, Mona El-Hashimy, Suddhasatta Acharyya, (unknown), Dirk Weber, Jan H.M. Schellens	1
18	Acute Postchallenge Hyperinsulinemia Predicts Weight Gain: A Prospective Study 1997 ·Diabetes ·Ronald J. Sigal, Mona El-Hashimy, Blaise C. Martin, J. Stuart Soeldner, Andrzej S. Królewski, James H. Warram	130
19	Factors Modifying the Risk of IDDM in Offspring of an IDDM Parent 1995 ·Diabetes ·Mona El-Hashimy, (unknown), Blaise C. Martin, Andrzej S. Królewski, James H. Warram	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact